Geron Swings to Profit as RYTELO Revenue Hits $60.1M, Opex Guidance Cut
GERN is trading near its 52-week low of $0.84 (14% above the low) on elevated volume (5.0× avg).
Summary
RYTELO net product revenue came in at $60.2 million for Q3 2026, up 5% from Q2 and well above the $47.2 million booked a year earlier, with demand up 10% sequentially and ordering accounts up roughly 8% to about 1,700. The company posted net income of $1.4 million versus a $18.4 million loss a year ago, driven by the higher revenue and total operating expenses falling to $54.4 million from $61.1 million. Management reiterated full-year RYTELO revenue at the mid-to-high end of $220 million to $240 million and cut the 2026 opex range to $220 million to $230 million from $230 million to $240 million. Cash and marketable securities stood at $339.4 million at quarter end, up from $326.9 million on June 30. The release also recaps the October 28 discontinuation of the Phase 3 IMpactMF myelofibrosis trial, which leaves the story almost entirely dependent on RYTELO in lower-risk MDS; the new piece is the gated European launch, with Germany expected by year-end and France in 2027.
At the time of this announcement, GERN was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $597.5M. The 52-week trading range was $0.84 to $2.01. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.